Oruka Therapeutics, Inc. - 8-K Filing
On June 2, 2026, Oruka Therapeutics held its annual stockholder meeting where three proposals were voted on. Stockholders elected directors Lawrence Klein and Chris Martin with votes of 43,918,579 to 63,593 and 43,936,173 to 45,999 respectively; ratified the appointment of PricewaterhouseCoopers LLP as auditors (45,206,297 for vs. 39,637 against); and approved executive compensation on an advisory basis with 43,033,967 votes in favor. (Items: 5.07 Submission of Matters to a Vote of Security Holders)
Tickers: $ORKA